These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17944930)

  • 1. Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery.
    Goodsell A; Zhou F; Gupta S; Singh M; Malyala P; Kazzaz J; Greer C; Legg H; Tang T; Zur Megede J; Srivastava R; Barnett SW; Donnelly JJ; Luciw PA; Polo J; O'Hagan DT; Vajdy M
    Immunology; 2008 Mar; 123(3):378-89. PubMed ID: 17944930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.
    Gupta S; Janani R; Bin Q; Luciw P; Greer C; Perri S; Legg H; Donnelly J; Barnett S; O'Hagan D; Polo JM; Vajdy M
    J Virol; 2005 Jun; 79(11):7135-45. PubMed ID: 15890953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.
    Gupta S; Zhou F; Greer CE; Legg H; Tang T; Luciw P; zur Megede J; Barnett SW; Donnelly JJ; O'Hagan DT; Polo JM; Vajdy M
    AIDS Res Hum Retroviruses; 2006 Oct; 22(10):993-7. PubMed ID: 17067269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.
    Greer CE; Zhou F; Goodsell A; Legg HS; Tang Z; zur Megede J; Uematsu Y; Polo JM; Vajdy M
    Scand J Immunol; 2007 Dec; 66(6):645-53. PubMed ID: 17944814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 Gag-specific vaginal immunity and protection after local immunizations with sindbis virus-based replicon particles.
    Vajdy M; Gardner J; Neidleman J; Cuadra L; Greer C; Perri S; O'Hagan D; Polo JM
    J Infect Dis; 2001 Dec; 184(12):1613-6. PubMed ID: 11740739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector.
    Caley IJ; Betts MR; Irlbeck DM; Davis NL; Swanstrom R; Frelinger JA; Johnston RE
    J Virol; 1997 Apr; 71(4):3031-8. PubMed ID: 9060663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal and systemic anti-HIV responses in rhesus macaques following combinations of intranasal and parenteral immunizations.
    Vajdy M; Singh M; Kazzaz J; Soenawan E; Ugozzoli M; Zhou F; Srivastava I; Bin Q; Barnett S; Donnelly J; Luciw P; Adamson L; Montefiori D; O'Hagan DT
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1269-81. PubMed ID: 15588349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced mucosal and systemic immune responses to Helicobacter pylori antigens through mucosal priming followed by systemic boosting immunizations.
    Vajdy M; Singh M; Ugozzoli M; Briones M; Soenawan E; Cuadra L; Kazzaz J; Ruggiero P; Peppoloni S; Norelli F; del Giudice G; O'Hagan D
    Immunology; 2003 Sep; 110(1):86-94. PubMed ID: 12941145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine.
    Ljungberg K; Whitmore AC; Fluet ME; Moran TP; Shabman RS; Collier ML; Kraus AA; Thompson JM; Montefiori DC; Beard C; Johnston RE
    J Virol; 2007 Dec; 81(24):13412-23. PubMed ID: 17913817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.
    Perri S; Greer CE; Thudium K; Doe B; Legg H; Liu H; Romero RE; Tang Z; Bin Q; Dubensky TW; Vajdy M; Otten GR; Polo JM
    J Virol; 2003 Oct; 77(19):10394-403. PubMed ID: 12970424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
    Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
    Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.
    Jones DI; Pollara JJ; Johnson-Weaver BT; LaBranche CC; Montefiori DC; Pickup DJ; Permar SR; Abraham SN; Maddaloni M; Pascual DW; Staats HF
    J Virol; 2019 Jul; 93(14):. PubMed ID: 31068425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization.
    Kuklin N; Daheshia M; Karem K; Manickan E; Rouse BT
    J Virol; 1997 Apr; 71(4):3138-45. PubMed ID: 9060677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity.
    Singh M; Vajdy M; Gardner J; Briones M; O'Hagan D
    Vaccine; 2001 Nov; 20(3-4):594-602. PubMed ID: 11672926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
    Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
    J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target.
    Manocha M; Pal PC; Chitralekha KT; Thomas BE; Tripathi V; Gupta SD; Paranjape R; Kulkarni S; Rao DN
    Vaccine; 2005 Dec; 23(48-49):5599-617. PubMed ID: 16099080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
    Staats HF; Nichols WG; Palker TJ
    J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral DNA vaccination promotes mucosal and systemic immune responses to HIV envelope glycoprotein.
    Kaneko H; Bednarek I; Wierzbicki A; Kiszka I; Dmochowski M; Wasik TJ; Kaneko Y; Kozbor D
    Virology; 2000 Feb; 267(1):8-16. PubMed ID: 10648178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity.
    Devito C; Zuber B; Schröder U; Benthin R; Okuda K; Broliden K; Wahren B; Hinkula J
    J Immunol; 2004 Dec; 173(11):7078-89. PubMed ID: 15557206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine.
    Greenway TE; Eldridge JH; Ludwig G; Staas JK; Smith JF; Gilley RM; Michalek SM
    Vaccine; 1998 Aug; 16(13):1314-23. PubMed ID: 9682396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.